Serum crosslinked N-terminal telopeptide of type 1 collagen for evaluation of bone loss in hemodialysis patients using dual-energy X-ray absorptiometry

Dialysis and Transplantation

Volumn 36, Issue 4, 2007, Pages 217-220

  Nakai, Tsuyoshi ^a   Kanbara, Nobuaki ^b  

^a OSAKA POLICE HOSPITAL   (Japan)

^b Kanbara Hospital   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ALKALINE PHOSPHATASE; AMINO TERMINAL TELOPEPTIDE; CALCIUM; PARATHYROID HORMONE; PHOSPHORUS;

ADULT; AGED; ALKALINE PHOSPHATASE BLOOD LEVEL; ARTICLE; BODY MASS; BONE DENSITY; CALCIUM BLOOD LEVEL; CHRONIC GLOMERULONEPHRITIS; CONTROLLED STUDY; DIABETES MELLITUS; DUAL ENERGY X RAY ABSORPTIOMETRY; HEMODIALYSIS; HUMAN; MAJOR CLINICAL STUDY; NEPHROSCLEROSIS; OSTEOLYSIS; PARATHYROID HORMONE BLOOD LEVEL; PHOSPHATE BLOOD LEVEL; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RENAL OSTEODYSTROPHY; TREATMENT DURATION;

EID: 54549104782     PISSN: 00902934     EISSN: None     Source Type: Journal    
DOI: 10.1002/dat.20122     Document Type: Article

References (14)

1. Piraino B, Chen T, Cooperstein L, Seger G, Pushett J. Fractures and vertebral bone mineral density in patients with renal osteodystrophy. Clin Nephrol. 1988;30:57-62.
2. Fogelman I, Blake GM. Different approaches to bone densitometry. J Nucl Med. 2000;41:2015-2025.
3. Parfitt AM. A structural approach to renal bone disease. J Bone Miner Res. 1988;13:1213-1220.
4. Looker AC, Bauer DC, Chesnut CH 3rd, et al. Clinical use of biochemical markers of bone remodeling: current status and future directions. Osteoporos Int. 2000;11:467-480.
5. Gorai I, Nonaka K, Kishimoto H, Sakata H, Fujii Y, Fujita T. Cut-off values determined for vertebral fracture by peripheral quantitative computed tomography in Japanese women. Osteoporos Int. 2001;12:741-748.
6. Watts NB. Clinical utility of biochemical markers of bone remodeling. Clin Chem. 1999;45:1359-1368.
7. Chesnutt CH 3rd, Bell NH, Clark GS, et al. Hormone replacement therapy in postmenopausal women: Urinary N-telopeptide of type 1 collagen monitors therapeutic effect and predicts response of bone mineral density. Am J Med. 1997;102:29-37.
8. Greenspan SL, Parker RA, Fergason L, Rosen HN, Maitland-Ramsey L, Karpf DB. Early changes in biochemical markers of bone turnover predict the long-term response to alendronate therapy n representative elderly women: A randomized clinical trial. J Bone Miner Res. 1998;13:1431-1438.
9. Montagnani A, Gonnelli S, Capello C, et al. A new serum assay to measure N-terminal fragment of telopeptide of type 1 collagen in patients with renal osteodystrophy. Eur J Intern Med. 2003;14:172-177.
10. Maeno Y, Inaba M, Okuno S, Yamakawa T, Ishimura E, Nishizawa Y. Serum concentrations of cross-linked N-telopeptides of type 1 collagen: New marker for bone resorption in hemodialysis patients. Clin Chem. 2005;51:12 2312-2317.
11. Nakashima A, Yorioka N, Mizutani T, Yamagata Z, Ueno T, Takasugi N. Serum cross-linked N-terminal telopeptide of type 1 collagen for evaluation of renal osteodystrophy in hemodialysis patients. Nephron Clin Pract. 2005;99:78-85.
12. Clemens JD, Herrick MV, Singer FR, Eyre DR. Evidence that serum NTx (collagen type 1 N-telopeptides) can act as an immunochemical marker bone resorption. Clin Chem. 1997;43:2058-2063.
13. Eastell R, Mallinak N, Weiss S, et al. Biological variability of serum and urinary N-telopeptides of type 1 collagen in postmenopausal women. J Bone Miner Res. 2000;15:594-598.
14. Atley LM, Mort JS, Lalumiere M, Eyre DR. Proteolysis of human bone collagen by cathepsin K: Characterization of the cleavage sites generating the cross-linked N-telopeptide neoepitope. Bone. 2000;26:241-247.